CERN has begun testing a strain of medical cannabis for cancer, a move that comes as some experts question the effectiveness of its most common ingredient.
Cancer patients have been using the herb to treat nausea and vomiting and relieve pain.
They can now grow their own cannabis and enjoy the high without the side effects associated with conventional cannabis.
The cannabis strain developed by CERN, known as Regeneron, was approved in February by a panel of experts.
It is the first of its kind and has been tested at a CERN research lab in Switzerland.CERN spokeswoman Marie-Paule De Vos said in a statement that the medical cannabis strain was developed at the CERN Biomedical Research Centre, or CERN BRC.
“Cancer treatment can be complicated, so we developed a strain to overcome this,” De VOS said.
“It is the only one with the active ingredient that has been studied in the laboratory, which means we are certain it is safe for the human body.”
In order to increase the effectiveness and safety of our new cannabis strain, CERN researchers have tested it in a small number of patients.
“The plant has already been tested in some patients who have been given the medicine to ease symptoms of cancer, such as nausea and pain.
The company behind Regeneron said that in its first trial in January, patients who were given Regeneron showed significant improvement in symptoms and improved quality of life.
It is unclear whether the Cern scientists have yet tested the cannabis strain for cancer.
Cern’s Biomedical research centre in Switzerland has produced a strain called Regeneron which has been approved by the European Medicines Agency.
The compound is a synthetic form of THC, the psychoactive ingredient in marijuana.
The new strain has been bred from a strain developed in a different lab at CERN in 2013.
The company says it is still in the testing phase, but that the cannabis has shown significant improvement.
The European Medicine Agency has set a two-year deadline for all countries to begin commercial cannabis production.